PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 73485

Title: The impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05872759

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: Italy

Author’s Country/Territory: Ireland

Manuscript submission date: 2021-12-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-12-12 12:02

Reviewer performed review: 2021-12-24 17:06

Review time: 12 Days and 5 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
</tbody>
</table>

Re-review: Yes [ ] No
SPECIFIC COMMENTS TO AUTHORS
The authors propose an interesting study exploring the role of hypofractionation and immunotherapy in oesophageal adenocarcinoma. The results of this study provide a preclinical basis for randomised trials using hypofractionated treatment schedules and/or adding immunotherapy to conventional radiochemotherapy. The only useful addition, for future clinical use of the study results, is to discuss the possible patient toxicity scenarios of a hypofractionated approach + concomitant immunotherapy.
**Name of journal:** World Journal of Gastroenterology  
**Manuscript NO:** 73485  
**Title:** The impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma  
**Provenance and peer review:** Invited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 03767590  
**Position:** Editorial Board  
**Academic degree:** MD, PhD  
**Professional title:** Associate Professor  
**Reviewer’s Country/Territory:** South Korea  
**Author’s Country/Territory:** Ireland  
**Manuscript submission date:** 2021-12-03  
**Reviewer chosen by:** AI Technique  
**Reviewer accepted review:** 2021-12-25 23:19  
**Reviewer performed review:** 2021-12-31 06:23  
**Review time:** 5 Days and 7 Hours  

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[X] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[X] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[X] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[X] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
In the present manuscript, Donlon et al. evaluated the immunologic effect of hypofractionated radiotherapy in oesophageal adenocarcinoma. English in this paper is well written, and experiments are very well described. The figures are of quality and data are exposed in a clear manner. Specific major concerns: In the Figure 2, these experiments should be performed in the OAC xenograft model instead of cell lines because the anticancer effect of ICI is induced in the situation of the presence of CD8+ T cells. What is the scientific rationale in the experimental design? If the experimental design in Figure 2 has a scientific rationale, what mechanisms might explain the induction of anti-cancer efficacy of the combined RT and ICI in an experimental system without CD8+ T cell? Some minor concerns: Can you provide the original dot plots of Flow cytometry in Figure 1?